Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022
暂无分享,去创建一个
[1] A. Brandes,et al. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream? , 2022, Immunotherapy.
[2] Jennie W. Taylor,et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter , 2022, Neuro-oncology.
[3] Shazia Rafique,et al. Viruses as tools in gene therapy, vaccine development, and cancer treatment , 2022, Archives of Virology.
[4] Liang Rong,et al. Emerging therapies for glioblastoma: current state and future directions , 2022, Journal of Experimental & Clinical Cancer Research.
[5] R. Kassubek,et al. First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis , 2022, Brain sciences.
[6] A. Brandes,et al. Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date? , 2022, Drugs.
[7] A. Brandes,et al. Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance , 2022, Frontiers in Oncology.
[8] Mariella G. Filbin,et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas , 2022, Nature.
[9] A. Kazemian,et al. Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis , 2022, Current oncology.
[10] J. Olson,et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults , 2021, Journal of Neuro-Oncology.
[11] Mu Fengqun,et al. Efficacy and safety of bevacizumab combined with other therapeutic regimens for treatment of recurrent glioblastoma: A network meta-analysis. , 2021, World neurosurgery.
[12] A. Drilon,et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors , 2021, Neuro-oncology.
[13] A. Sloan,et al. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments , 2021, Journal of Neuro-Oncology.
[14] A. Brandes,et al. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem , 2021, Expert review of anticancer therapy.
[15] S. Fox,et al. BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives? , 2021, Frontiers in Oncology.
[16] G. Pavesi,et al. GD2 CAR T cells against human glioblastoma , 2021, npj Precision Oncology.
[17] E. Jabłońska,et al. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells , 2021, International journal of molecular sciences.
[18] J. Sampson,et al. Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma , 2021, Cancers.
[19] M. Nagane,et al. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial , 2021, Cancer science.
[20] Z. Ram,et al. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial , 2021, Frontiers in Oncology.
[21] J. Eberwine,et al. Commentary: "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and Its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing. , 2021, Neurosurgery.
[22] H. Daldrup-Link,et al. Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. , 2021, Pharmacological research.
[23] C. Driver,et al. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma , 2021, Pharmaceuticals.
[24] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[25] S. Di Bartolomeo,et al. Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update , 2021, International journal of molecular sciences.
[26] A. Brandes,et al. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. , 2021, European journal of cancer.
[27] Daniel J Verdon,et al. Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma , 2021, Clinical & translational immunology.
[28] D. Tache,et al. Updated Insights on EGFR Signaling Pathways in Glioma , 2021, International journal of molecular sciences.
[29] Yuan Wu,et al. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future , 2020, Frontiers in Immunology.
[30] Fiona A. Desland,et al. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy , 2020, International journal of molecular sciences.
[31] Ashley R Sutherland,et al. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting , 2020, International journal of molecular sciences.
[32] Xueran Chen,et al. Molecular subtyping of glioblastoma based on immune-related genes for prognosis , 2020, Scientific Reports.
[33] D. Corcoran,et al. Efficacy of osimertinib against EGFRvIII+ glioblastoma , 2020, Oncotarget.
[34] Fusheng Liu,et al. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas , 2020, Cell Death & Disease.
[35] D. Barilà,et al. SRC Kinase in Glioblastoma: News from an Old Acquaintance , 2020, Cancers.
[36] G. Russo,et al. SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines , 2020, International journal of molecular sciences.
[37] Lianrong Wang,et al. Advances in drug development for targeted therapies for glioblastoma. , 2020, Medicinal research reviews.
[38] M. Weller,et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.
[39] H. Engelhard,et al. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma , 2020, Molecular Neurobiology.
[40] M. Stuschke,et al. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma , 2019, Journal of Cancer Research and Clinical Oncology.
[41] Zev A. Binder,et al. Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma , 2019, CNS oncology.
[42] K. Bencardino,et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] G. Russo,et al. Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line , 2019, International journal of molecular sciences.
[44] B. Melosky,et al. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. , 2019, Clinical lung cancer.
[45] C. Pratilas,et al. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors , 2019, Cancers.
[46] Christopher M. Jackson,et al. Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.
[47] Marcela V Maus,et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity , 2019, Nature Biotechnology.
[48] Christine E. Brown,et al. CAR T cells for brain tumors: Lessons learned and road ahead , 2019, Immunological reviews.
[49] M. Deng,et al. Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial , 2019, Journal of Cancer.
[50] C. Zamperini,et al. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor , 2019, Cancers.
[51] A. Iafrate,et al. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma , 2019, Acta neuropathologica communications.
[52] C. June,et al. Emerging Cellular Therapies for Cancer. , 2019, Annual review of immunology.
[53] K. Schalper,et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma , 2019, Nature Medicine.
[54] D. C. Adamson,et al. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma , 2019, Expert opinion on investigational drugs.
[55] P. Wen,et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.
[56] J. Pichler,et al. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. , 2018, The oncologist.
[57] Juanjuan Zhao,et al. Universal CARs, universal T cells, and universal CAR T cells , 2018, Journal of Hematology & Oncology.
[58] G. Pavesi,et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors , 2018, Cancer Gene Therapy.
[59] D. Ottaviani,et al. Harnessing the immune system in glioblastoma , 2018, British Journal of Cancer.
[60] A. Drilon,et al. NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.
[61] G. Linette,et al. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges , 2018, Neuro-oncology.
[62] William P. Accomando,et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC , 2018, Neuro-oncology.
[63] E. Wong,et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma , 2018, Journal of Neuro-Oncology.
[64] Zhihong Chen,et al. Immune Microenvironment in Glioblastoma Subtypes , 2018, Front. Immunol..
[65] Neil Humphryes-Kirilov,et al. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[66] Ivana Jovčevska. Sequencing the next generation of glioblastomas , 2018, Critical reviews in clinical laboratory sciences.
[67] R. Geffers,et al. A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report , 2018, Cellular Oncology.
[68] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[69] Steven P. Angus,et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma , 2017, Neuro-oncology.
[70] D. Dimitrov,et al. CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature medicine.
[71] Asher Mullard. FDA approves first CAR T therapy , 2017, Nature Reviews Drug Discovery.
[72] J. Yang,et al. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. , 2017, Translational research : the journal of laboratory and clinical medicine.
[73] Ying Sun,et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications , 2017, Theranostics.
[74] Manfred Westphal,et al. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise , 2017, CNS Drugs.
[75] R. Grossman,et al. HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.
[76] K. Mansfield,et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.
[77] A. Drilon,et al. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target , 2017, Nature Communications.
[78] J. Moffat,et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] S. To,et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development , 2017, Molecular Cancer.
[80] Michel Sadelain,et al. Therapeutic T cell engineering , 2017, Nature.
[81] James X. Sun,et al. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. , 2017, JCI insight.
[82] B. Kamińska,et al. Immune microenvironment of gliomas , 2017, Laboratory Investigation.
[83] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[84] S. Albelda,et al. CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.
[85] G. Liang,et al. Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients. , 2016, Oncology letters.
[86] K. Chester,et al. Ipilimumab and Bevacizumab in Glioblastoma. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[87] In-Hee Lee,et al. Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.
[88] T. Mikkelsen,et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma , 2016, Science Translational Medicine.
[89] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[90] Aizhen Liu,et al. Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation , 2016, Front. Oncol..
[91] J. Markert,et al. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.
[92] E. Kirson,et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells , 2015, Scientific Reports.
[93] M. Sadelain,et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.
[94] B. Mayer,et al. The discovery of modular binding domains: building blocks of cell signalling , 2015, Nature Reviews Molecular Cell Biology.
[95] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[96] D. Campana,et al. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing , 2015, Oncotarget.
[97] J. Sarkaria,et al. Dasatinib in recurrent glioblastoma: failure as a teacher. , 2015, Neuro-oncology.
[98] K. Aldape,et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). , 2015, Neuro-oncology.
[99] Michel Sadelain,et al. The pharmacology of second-generation chimeric antigen receptors , 2015, Nature Reviews Drug Discovery.
[100] C. Sheridan. First oncolytic virus edges towards approval in surprise vote , 2015, Nature Biotechnology.
[101] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[102] Jill S Barnholtz-Sloan,et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.
[103] W. Mason,et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. , 2014, Neuro-oncology.
[104] Shawn M. Gillespie,et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.
[105] R. Coffey,et al. Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. , 2014, Annual review of physiology.
[106] G. Shurin,et al. Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer , 2013, Cancer Microenvironment.
[107] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[108] P. Sorensen,et al. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation , 2012, Oncogene.
[109] C. Wirtz,et al. Erlotinib in glioblastoma: lost in translation? , 2011, Anti-cancer agents in medicinal chemistry.
[110] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[111] Suzanne Kamel-Reid,et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation , 2009, Cancer Chemotherapy and Pharmacology.
[112] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[113] J. Kuratsu,et al. Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas , 2008, The Journal of pathology.
[114] B. Thompson,et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[115] E. Dekel,et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors , 2007, Proceedings of the National Academy of Sciences.
[116] B. Seliger,et al. Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.